MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I
Johannes Brägelmann, Carina Lorenz, Sven Borchmann et al. · Nature Communications · 2021
Abstract Kinase inhibitors suppress the growth of oncogene driven cancer but also enforce the selection of treatment resistant cells that are thought to promote tumor relapse in patients. Here, we report transcriptomic and functional genomics analyses of cells and tumors within their microenvironment across different genotypes that persist during kinase inhibitor treatment. We uncover a conserved, MAPK/IRF1-mediated inflammatory response in tumors that undergo stemness- and senescence-associated reprogramming. In these tumor cells, activation of the innate immunity sensor RIG-I via its agonist IVT4, triggers an interferon and a pro-apoptotic response that synergize with concomitant kinase inhibition. In humanized lung cancer xenografts and a syngeneic Egfr-driven lung cancer model these effects translate into reduction of exhausted CD8+ T cells and robust tumor shrinkage. Overall, the mechanistic understanding of MAPK/IRF1-mediated intratumoral reprogramming may ultimately prolong the efficacy of targeted drugs in genetically defined cancer patients.
Cited by 74 works. doi:10.1038/s41467-021-25728-8 Open-access PDF
Authors
- Johannes Brägelmann
- Carina Lorenz
- Sven Borchmann
- Kazuya Nishii
- Julia Wegner
- Lydia Meder
- Jenny Ostendorp
- David Ast
- Alena Heimsoeth
- Takamasa Nakasuka
- Atsuko Hirabae
- Sachi Okawa
- Marcel Andre Dammert
- Dennis Plenker
- Sebastian Klein
- Philipp Lohneis
- Laura Godfrey
- Jan Förster
- Marija Trajkovic‐Arsic
References
- Robust enumeration of cell subsets from tissue expression profiles
- The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway